Peptide Research Literature Index
A structured, dated index of the research-peptide landscape

Does moving a drug to somebody who is not a patient need a license? Federal law says yes, writes the test as six words, and lists nineteen exceptions — not one of which is research

Reference page · published 2026-10-21

Disclosure: this index is operated by Artemis Labs, which sells research compounds to laboratories. Artemis Labs has no connection to any person or company named on this page, sells none of the products they sold, and sells no controlled substance of any kind. Nothing here is legal advice, and this page deliberately stops short of one question. The rules quoted below gate on whether an article is a prescription drug, which is a contested question this page does not resolve and does not pretend to. Whether any of this reaches a particular seller or a particular buyer is a question for a lawyer looking at that seller’s actual facts, and the section on what the evidence does not show sets out, at length, every reason the answer may be no. Every quotation below is verbatim from the United States Code or from a Department of Justice press release, each of which was fetched and read for this page on October 21, 2026 and each of which is listed under Sources. The criminal complaint described in one section below contains allegations only; no disposition for it is held in this index.

Short answer: yes, and the test is unusually blunt. Federal law says No person may engage in wholesale distribution of a drug subject to subsection (b)(1) in any State unless such person— (i) (I) is licensed by the State from which the drug is distributed. And wholesale distribution is then defined as the distribution of a drug subject to subsection (b) to a person other than a consumer or patient, or receipt of a drug subject to subsection (b) by a person other than the consumer or patient. There is no claim in that test, no label, no assay, no purity number and no advertising. There is a drug, a person who is not a patient, and a piece of paper from a state. The section then lists nineteen things that do not count, lettered (A) through (S) — and the words research, laboratory, scientific, chemical analysis and investigational appear zero times among them. But everything in the sentence hangs on the phrase a drug subject to subsection (b), and that is the same contested gate the rest of this index turns on.

Most of the enforcement records collected in this index are about words. What a website said. What a label claimed. What a review promised. The rule on this page is different, and that is why it is worth a page of its own: it is a rule you can break in complete silence. You can say nothing, promise nothing, test everything, label everything accurately, and still violate it, because the only thing it asks is whether a state gave you a license.

That makes it the one rule in this collection where a careful seller gets no credit for being careful. So it is worth knowing exactly how it is built, and — just as important — how often anyone has actually been punished under it. Those two answers point in opposite directions, and we report both.

The chain, one link at a time

Nothing about this rule lives in one place. It takes four sections of the United States Code to get from the duty to the prison sentence, and each one points at the next. We fetched all four and read them, instead of summarizing somebody else’s summary. Here is the whole chain in order.

What it doesWhere it livesWhat it says
The duty21 U.S.C. § 353(e)(1)(A) No person may engage in wholesale distribution of a drug subject to subsection (b)(1) in any State unless such person— (i) (I) is licensed by the State from which the drug is distributed; or (II) if the State from which the drug is distributed has not established a licensure requirement, is licensed by the Secretary
The definition — and the whole test21 U.S.C. § 353(e)(4) the term “ wholesale distribution ” means the distribution of a drug subject to subsection (b) to a person other than a consumer or patient, or receipt of a drug subject to subsection (b) by a person other than the consumer or patient
The prohibited act21 U.S.C. § 331(t) the distribution of drugs in violation of section 353(e) of this title … or the failure to otherwise comply with the requirements of section 353(e) of this title
The penalty21 U.S.C. § 333(a) and § 333(b)(1)(D) Any person who violates a provision of section 331 of this title shall be imprisoned for not more than one year or fined not more than $1,000, or both. — and, separately, knowingly distributing drugs in violation of section 353(e)(1) of this title , shall be imprisoned for not more than 10 years or fined not more than $250,000, or both.

Two things about that table are worth saying out loud, because both of them are easy to get wrong and we got one of them wrong ourselves before reading the bytes.

First, the prohibition never uses the words. Section 331 is the list of things the Food, Drug, and Cosmetic Act forbids, and the phrase wholesale distribution appears in it zero times. Paragraph (t) does its work entirely by cross-reference — it points at § 353(e) twice in the same paragraph and leaves the content there. Anyone searching the list of federal crimes for the phrase itself will not find it.

Second, the ten-year tier needs knowledge and the one-year tier does not. The duty at § 353(e)(1) contains no mental state at all: the words knowing, intent and willful appear zero times in it, and zero times in the definition at § 353(e)(4) either. Section 333(a)(1) then attaches a one-year ceiling to any violation of § 331, with no mental state required. But § 333(b)(1)(D) — the provision that carries the ten-year ceiling — begins with the word knowingly. So this is not, as it is sometimes described, a crime whose only element is a missing license. A missing license is the only element of the misdemeanor. The felony also requires knowledge.

Third, and we only found this by reading the amendment notes: the ten-year provision does not point where it used to point. Section 333’s own record of changes says, for the exact subparagraph quoted above, 2013—Subsec. (b)(1)(D). Pub. L. 113–54 substituted “353(e)(1)” for “353(e)(2)(A)”. That public law is dated Nov. 27, 2013. So the felony provision aimed somewhere else until late 2013, and — as the next section shows — the only conviction this lane has produced was imposed four months earlier. The chain set out in the table above has never produced a conviction in the form it now takes.

One caution on that, because it is the kind of thing that is easy to overstate. Section 333 also carries a note saying an amendment to it by Pub. L. 113–54 shall take effect on January 1, 2015. That note identifies the amendment it governs by a section of the public law, and the change-record entry for subparagraph (b)(1)(D) cites no section of the public law at all. So whether that later effective date governs this particular substitution is not something the text we read establishes, and we are not going to assert it either way.

That three-step structure will be familiar if you have read what turns a misbranding charge into a felony. It is the same architecture — a strict-liability floor, an intent-based middle tier, and a far higher ceiling for conduct done knowingly. That page covers the first two tiers for a different charge. This one adds the third, which does not appear anywhere else in this index.

The test is six words long, and it took four documents to find them

The sentence that decides who this rule covers is other than a consumer or patient. Six words. And it is not where a reasonable person would look for it.

It is not in § 331, the list of prohibited acts: zero occurrences. It is not in § 360eee, the definitions section that defines wholesale distributor: zero occurrences there either, because that definition passes the question straight back by defining a wholesale distributor as a person engaged in wholesale distribution (as defined in section 353(e)(4). The phrase occurs exactly once in the whole of § 353, buried at paragraph (e)(4), underneath three paragraphs of licensing procedure, reporting schedules and fee authority.

We say that because of how easy it is to read two of these sections, find nothing, and conclude the test is something else. It is a four-document trail, and the shortcut does not work.

The definition has two halves, and the second one is about receiving

Read the definition again slowly, because almost every description of this rule quotes only the first half:

the distribution of a drug subject to subsection (b) to a person other than a consumer or patient, or receipt of a drug subject to subsection (b) by a person other than the consumer or patient

On the face of that sentence, receiving a drug is wholesale distribution too, if you are not the consumer or the patient. The regulated act is not only pushing product out; it is also taking product in. Whether the ten-year tier reaches a pure receipt is a genuine open question on the text, and we are not going to resolve it here: § 333(b)(1)(D)’s own verb is knowingly distributing, not receiving, and the word receipt appears five times elsewhere in § 333 without once referring to this. We read all five. None of them answers it.

Nineteen exceptions, and the word that is not among them

After the definition, § 353(e)(4) says the term does not include a list. We counted the top-level items by script and got nineteen, lettered (A) through (S). They are a map of the lawful drug supply chain: moving product inside one company, moving it between hospitals under common control, emergency medical reasons, dispensing on a prescription, a retail pharmacy sending a small quantity to a practitioner, charitable transfers, a dispenser or hospital buying for its own use, a manufacturer distributing its own drug, a logistics provider or common carrier that never takes ownership, an authorized repackager, salable returns, medical convenience kits, three narrowly drawn product categories that the section names one by one, medical gas, pure administrative order-and-payment services, and transfers to a repackager working for a hospital.

Here is what is missing. We scanned the whole exclusion list for the vocabulary a research seller or a research buyer would instinctively reach for:

Word searched in the nineteen exceptionsTimes it appears
research0
laboratory0
scientific0
chemical analysis0
investigational0
teaching0
not for sale0
in vitro0
control: hospital7
control: repackag3

Those zeros are readings, not broken searches. The same script, over the same span of text, found hospital seven times and repackag three times, and a meaningless control string zero times. And the word research appears zero times in the entirety of § 353 — not just in the exception list.

Three of the nineteen are near misses, not matches, and they are the ones worth naming because a reader may think one of them fits:

It is worth noticing how this compares with the registration rules covered at who has to register with FDA as a drug establishment. There, a research exemption genuinely exists — and it ends with the words and not for sale, which is the whole problem. Here there is no research exemption to qualify. There is simply nothing.

Everything hangs on one phrase, and it is the contested one

Every sentence above is gated on five words: a drug subject to subsection (b). If an article is not a drug subject to § 353(b)(1), none of this attaches to it, and the whole page is about somebody else. So it matters a great deal what that subsection says, and it is not what most people assume.

Section 353(b)(1) defines the category with two alternative limbs, and we quote both because the difference between them is the single most consequential thing on this page:

A drug intended for use by man which— (A) because of its toxicity or other potentiality for harmful effect, or the method of its use, or the collateral measures necessary to its use, is not safe for use except under the supervision of a practitioner licensed by law to administer such drug ; or (B) is limited by an approved application under section 355 of this title to use under the professional supervision of a practitioner licensed by law to administer such drug

Limb (B) is the one everybody pictures: a drug with an approved application, where the approval itself restricts it to professional supervision. The phrase approved application occurs once in that limb.

Limb (A) contains the phrase zero times. It is not an approval test at all. It is a test about the article’s own properties — whether it is safe to use without supervision — and it is joined to limb (B) by the word or. So an article with no approval of any kind can still fall inside subsection (b)(1), through limb (A).

What limb (A) does require is the opening phrase: intended for use by man. And that is the hinge, because intended use is not a question about what a molecule is. It is a question about evidence of intent, and the regulation that governs it is the subject of this index’s page on whether a page has to promise something before FDA calls it a drug claim. Under that regulation, intent may be shown by a seller’s expressions, by the design or composition of the article, or by the circumstances surrounding its distribution.

Which produces the structural point of this whole page, and we state it as a chain of ifs rather than a conclusion, because that is what it is. If an article is intended for use by man, and if it is unsafe without supervision, then it is subject to subsection (b)(1) with no approval required, and then moving it to anyone who is not a consumer or patient is wholesale distribution, and then that requires a state license. Each of those steps is contested. We are not asserting that the chain closes. We are pointing out that it is a chain nobody in this market talks about, and that not one link in it asks what anybody said.

Now the other half: what has anyone actually been punished for?

A statute is not an enforcement record, and this index exists to report records. So we went to the Department of Justice’s press-release interface and asked it for every release whose headline contains the phrase wholesale distribution.

The answer, printed from the response and not counted off a page: nine releases. Page two returned zero rows, so nine is the whole channel. A deliberately meaningless headline query returned a count of zero, so the filter is filtering.

Then we read all nine bodies and asked a simple question of each one: what job is the word wholesale actually doing here?

DateReleaseWhat the body is really about
2013-08-01Pleasant Grove man sentenced after pleading guilty to unlicensed wholesale distribution of prescription drugs (D. Utah) This rule. The only one.
2014-01-16Charges against a former warehouse manager of a prescription drug wholesale distribution company over falsified pedigrees (S.D.N.Y.) The record-keeping half of the same statutory neighborhood. A complaint; allegations only.
2018-07-31Three Canadians and their company sentenced for wholesale distribution of misbranded prescription drugs and money laundering (W.D. Pa.) A misbranding case. Wholesale describes the quantity.
2019-10-02Wholesale fentanyl distributor convicted (D. Md.) Controlled substances. Not this.
2020-01-16Wholesale fentanyl distributor sentenced to 35 years (D. Md.) Controlled substances. Not this.
2021-11-02Leader of a wholesale drug distribution network pleads guilty — synthetic cannabinoids (E.D. Va.)Controlled substances. Not this.
2022-03-02Leader of a wholesale drug distribution network sentenced (E.D. Va.) The same enterprise as the row above.
2024-08-20Shreveport wholesale drug distribution company settles over failure to report suspicious opioid orders (E.D. La.) A controlled-substances reporting settlement. Not this.
2026-09-03Charge of wholesale drug distribution from a restaurant in Tulare County (E.D. Cal.)No markers of the Food, Drug, and Cosmetic Act in the body at all.

Measured across those nine bodies, not their headlines:

So: a headline census on the phrase that names this rule returns nine federal announcements, and exactly one of them is a conviction for it.

The one conviction: a year and a day, for one shipment

The release is dated August 1, 2013, and reports a sentence imposed Wednesday afternoon — the Wednesday before that date was July 31, 2013. It runs 4,640 characters, uses some form of license seven times and the phrase wholesale distribut six times, and names no statute number anywhere. The chain set out at the top of this page is the law as we read it, not as the Department of Justice cited it.

What it says, verbatim:

Michael Lawrence O’Donnell, age 63, of Pleasant Grove, Utah, who admitted he distributed prescription pharmaceutical drugs he obtained in Europe to healthcare professionals around the United States without a license, will serve a year and a day in federal prison.

On the license itself, and note which government issues it:

At the time he was distributing the drugs around the United States, O’Donnell admitted that he did not possess a license from the State of Utah to engage in the wholesale distribution of the drugs.

That is the element, satisfied, in one sentence. A federal prison term, turning on a document a state did not issue. It is the clearest illustration in this collection of a point that sounds like a technicality and is not: § 353(e)(1)(A)(i) (I) requires a person to be licensed by the State from which the drug is distributed, so the content of the federal duty is written by state law. Which state’s law, and what that state’s law says, is not a question this page can answer for anybody, and we did not read any state statute for it.

The release also explains the Act it sits under, and names it without a section number:

To prevent the distribution of stolen, counterfeit, sub-potent, unapproved, expired or otherwise unlawful drugs, Congress enacted the Prescription Drug Marketing Act (PDMA). The Act prohibits individuals from engaging in the wholesale distribution of prescription drugs in a particular state unless the individual is licensed by the state to do so.

Two more details matter. The buyers were professionals, which is precisely why the six-word test was met — the release records that prescription drug manufacturers generally distribute products to doctors, pharmacists, and hospitals through licensed wholesale distributors. And the count he actually pleaded to was a single parcel:

He pleaded guilty to a count in the indictment that charged him with shipping Botox from Utah to a health care provider in New York in July 2006.

One shipment, one count. The products named in the plea agreement were Botox, Zometa, Gemzar, and Aranesp — four approved, branded, prescription products obtained in Europe. Keep that in mind when the counter-evidence section explains what this case does not establish.

The release quotes an FDA criminal-investigations official on why the agency cares, and the answer is about supply chains, not claims:

Unlicensed wholesalers, who import prescription drugs into the United States and further distribute them, introduce potentially substandard treatments into the stream of commerce, which, in turn, create potential health risks to the ultimate consumers of those drugs — Patrick Holland, Special Agent in Charge of FDA’s Office of Criminal Investigations Kansas City Office.

The case where “wholesale” is a quantity, not a charge

The 2018 release has wholesale distribution in its headline and is routinely counted as a case about this rule. Read the body and it is not. It runs 3,942 characters, uses wholesale quantit three times, uses wholesale distribut zero times, and uses a form of license exactly once. The charge, as announced:

charges of conspiring to distribute wholesale quantities of misbranded prescription drugs made for the foreign market and money laundering

That is a misbranding conspiracy. Wholesale is measuring volume. And the one licensing sentence in the document is not about the defendants at all:

None of the re-shippers was licensed in the United States to conduct this business.

The misbranding theory in it is worth recording for its own sake, because it needs no claim either: None of the prescription drugs met FDA approval because they were made and labeled for use outside of the United States. Country of labeling, not content of labeling. The sentences were three years probation and a fine of $55,000 each for the three individuals, with a $150,000 fine for the company and forfeiture of $4,235,000.

The other half of the statute: records, not licenses

The 2014 release is a criminal complaint, so everything in it is an allegation and no disposition is held here. It is included because it shows the neighboring duty that § 331(t) reaches in the same breath — the paper trail that follows a drug through the supply chain:

a scheme to falsify pedigrees for prescription drugs sold to pharmacies all over the country, including at least six pharmacies in New York City. The prescription drugs were diverted from illegal sources and made to appear, through pedigrees falsely documenting their transaction histories, as though they were obtained legitimately from authorized distributors through licensed wholesalers.

The alleged scale was more than $49 million worth of drugs. We record this limb as genuinely distant from the subject of this index for one reason: a falsified transaction history requires a branded, approved, diverted supply to document falsely. There is no analogue to that in a market of unapproved articles.

What does the evidence not show?

This is the section that matters most, and it is longer than the rest of the page for a reason. The statutory reading above is clean and the enforcement record behind it is thin. Here is every reason we can find to doubt that the first means much, stated as plainly as we can manage.

1. The gate is unresolved, and it is the whole thing. Every sentence on this page is conditional on an article being a drug subject to subsection (b). That question is contested, unlitigated in this market, and not resolved anywhere in this index. If the answer is no, this page describes a rule that does not apply. We are not able to tell you which it is, and anybody who tells you confidently should be asked what they read.

2. One conviction in thirteen years is not a trend. The entire headline census produced a single conviction on this count, in 2013, for a single shipment, by a defendant who was moving approved branded pharmaceuticals obtained abroad. The lane is real and it is narrow, and nothing in the record we read suggests it is growing.

3. The one conviction is about a different kind of product. Botox, Zometa, Gemzar and Aranesp are approved human prescription drugs with brand names. A drug with an approved human counterpart arrives at subsection (b)(1) through limb (B) almost automatically — the approval itself does the work. For an article with no approved counterpart, that scaffold is simply absent, and the government would have to win limb (A) on the article’s own properties and win the intended-use question first. This is the single biggest limit on the whole page, and nothing in the documents we read closes it.

4. The current text of the felony provision has never produced a conviction. As set out above, § 333(b)(1)(D) was amended in 2013 to point at § 353(e)(1) instead of § 353(e)(2)(A), by a public law dated November 27, 2013. The one conviction in this lane was imposed four months before that. Everything on this page about the ten-year tier is therefore a reading of a provision whose present wording has, so far as the record we gathered shows, never been applied to anyone in this area at all.

5. The felony needs knowledge, and we should not have had to discover that. This rule is widely described, including in a brief we ourselves were working from, as a crime whose only element is a missing state license. For the one-year misdemeanor under § 333(a)(1), that is right. For the ten-year felony under § 333(b)(1)(D), it is wrong: the provision begins with knowingly. We corrected this by reading § 333, and the correction cuts against the alarming version of the story.

6. Our headline census is a floor, and we can prove that, not just assert it. The Department of Justice interface we used matches headlines, not bodies, so any case whose headline uses different words is invisible to it. We have a concrete demonstration. A second query, on the phrase unlicensed wholesale, returned a release dated 2023-10-31, titled Unlicensed Wholesaler Sentenced To Prison For Distributing Foreign Unapproved New Drugs And Mail Fraud — a release the first query never returned. So the nine is not the lane.

7. And that 2023 release, read in full, makes the lane smaller rather than larger. Its headline contains both Unlicensed and Wholesaler. Its body is 1,856 characters long and contains the string unlicensed zero times, any form of licens zero times, and any form of wholesal zero times. The convictions it reports are mail fraud and introduction into interstate commerce of a foreign unapproved new drug. Those zeros are readings: the same measurement on the 2013 release finds unlicensed twice, so the search works. The licensing language in that case exists only in the Department’s headline. If you are counting cases in this lane by their headlines — and a headline query is the only interface most people have — you will count that one, and you will be wrong.

That is the same phenomenon this index documented for a different agency at what the Subject column in FDA’s warning letter list means: a filing label applied at publication whose words can appear nowhere in the document underneath. Two agencies, two filing systems, one lesson. The label on the folder is not evidence about the contents.

8. The two vocabularies barely meet. We also pulled the headline channels for without a license (164 releases) and misbranded (241 releases). Of the first fifty misbranded headlines returned, the number that also contain any form of wholesal is zero. The licensing lane and the labeling lane are, in the Department’s own public writing, almost entirely separate populations.

9. This index itself holds a further instance we could not re-verify tonight. Our own page on the Tailor Made Compounding warning letter records a guilty plea involving wholesale distribution of a prescription product to a clinic without a wholesaler’s license. We could not re-fetch a primary source for it for this page: the Department’s web pages return an automated bot-verification challenge to the machine we work from, and the release is not reachable through the headline interface that does work. It is therefore not counted in anything above, and it is flagged for verification rather than used. We mention it only because it is further evidence that a headline census undercounts.

10. No court has tested any of this against a research seller or a research buyer. Not one of the documents read for this page involves an article sold for laboratory use. The application of this chain to that market is our reading of statutory text, and statutory text is not precedent.

11. We did not read a single state statute. Since the federal duty borrows the content of state licensing law, the question of whether any state licensing scheme has a research-use carve-out is the question that would actually matter — and it is unanswered here. The federal list of exceptions is now fully read and contains no research vocabulary. That settles the federal half and leaves the state half entirely open.

Why this page exists at all

Almost every other page in this index helps a reader judge words — a vendor’s claims, a label, a review, a disclaimer. This page cannot do that, and that is the point of publishing it. The rule described here is indifferent to all of it.

We also checked whether we had already covered it, and we had not, by a wide margin. Across the 112 other pages built for this index, 353(e) appears 0 times, 331(t) 0 times, 333(b) 0 times, Prescription Drug Marketing Act 0 times, wholesale distributor 0 times, and licensed by the State 0 times. Those are measurements over the built corpus with a live control that fired on 105 of those 112 and a meaningless control that fired on none. A hundred and twelve pages of enforcement records, and the one federal rule in the area that does not care what you say had never once been named.

The honest commercial note, since this index is operated by a seller: a page explaining a rule that turns on paperwork rather than claims is not a comfortable page for anybody in this market to publish, including us. We publish it because a reader deciding who to buy research compounds from deserves to know which rules are about words and which are not, and because a limit we only mention when it is flattering is not a limit we have really disclosed.

Sources

Every document below was fetched on October 21, 2026 for this page and archived. Quotations are verbatim from these files.

Statements on this page about what a section says, what a release says, what either omits, and what number or date it carries were read off those files. Counts described as measured were computed over them by script, and every zero reported above was reported alongside a live control that returned non-zero in the same pass and a meaningless control that returned zero. The 2014 matter is a criminal complaint and contains allegations only. Nothing on this page is legal advice.

How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.